Skip to main content
. 2018 Nov 20;290(1):9–22. doi: 10.1148/radiol.2018181349

Figure 10:

Figure 10:

Immune-checkpoint inhibitor-related hepatitis in a patient with metastatic melanoma treated with ipilimumab and with markedly elevated liver function test levels at presentation. Coronal CT scan obtained after 2.7 months of ipilimumab therapy shows new periportal edema (black arrows), new periportal lymphadenopathy (white arrows), and hepatomegaly with trace perihepatic free fluid, demonstrating ipilimumab-related hepatitis.